Physician profile
Mason Weiss
NPI 1447256565
$5,656.02
in general payments reported to CMS, 2019-2025
34 companies · $515 in 2025
The $515 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,098 · 2020: $411 · 2021: $1,393 · 2022: $785 · 2023: $953 · 2024: $500 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,322.26 | 2019-2025 | Jeti Peripheral Catheter, Xact, Supera |
| Novartis Pharmaceuticals Corporation | $1,221.40 | 2019-2025 | |
| Pfizer INC. | $533.14 | 2019-2025 | |
| Novo Nordisk INC | $490.40 | 2020-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $304.27 | 2019-2023 | Xarelto |
| Medtronic, INC. | $243.33 | 2021 | |
| Amgen INC. | $230.35 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $168.45 | 2020-2025 | Brilinta, Farxiga |
| Endologix LLC | $139.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.30 | 2022-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $97.94 | 2019 | |
| Esperion Therapeutics, INC. | $93.75 | 2024-2025 | Nexletol |
| Akcea Therapeutics, INC. | $64.63 | 2019-2020 | |
| Abiomed | $62.98 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.30 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $51.18 | 2023-2025 | Amvuttra |
| Kestra Medical Technology Services, INC. | $51.16 | 2022-2025 | Assure Wcd |
| Angiodynamics, INC. | $43.89 | 2025 | Alphavac |
| Sanofi-Aventis U.S. LLC | $40.60 | 2019 | |
| Impulse Dynamics (USA) INC. | $39.19 | 2023 | Optimizer |
| Getinge USA Sales, LLC | $38.90 | 2020 | |
| Merck Sharp & Dohme LLC | $27.77 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.24 | 2025 | Jardiance |
| Gilead Sciences, INC. | $24.20 | 2019 | |
| Vifor Pharma, INC. | $23.83 | 2020 | |
| Astellas Pharma US INC | $22.83 | 2021 | |
| Preventice Services, LLC | $21.98 | 2021 | |
| Baxter Healthcare | $21.35 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Scpharmaceuticals INC. | $20.79 | 2023 | |
| Glaxosmithkline, LLC. | $20.57 | 2021 | |
| Shockwave Medical, INC | $19.37 | 2021 | |
| Bridgebio Pharma, INC. | $15.09 | 2025 | Attruby |
| Cardiovascular Systems INC. | $12.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.